Shares of AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) have been given an average recommendation of “Buy” by the twelve brokerages that are presently covering the firm. Five analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $35.40.

AMAG has been the topic of several analyst reports. Guggenheim initiated coverage on AMAG Pharmaceuticals in a report on Monday, November 7th. They issued a “buy” rating and a $42.00 target price on the stock. Jefferies Group lowered their price target on AMAG Pharmaceuticals from $58.00 to $45.00 and set a “buy” rating on the stock in a report on Wednesday, August 10th. Zacks Investment Research raised AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $26.00 price target on the stock in a report on Friday, August 12th. Leerink Swann reaffirmed an “outperform” rating and set a $36.00 price target on shares of AMAG Pharmaceuticals in a report on Thursday, October 13th. Finally, Needham & Company LLC initiated coverage on AMAG Pharmaceuticals in a report on Wednesday, October 26th. They set a “buy” rating and a $40.00 price target on the stock.

AMAG Pharmaceuticals (NASDAQ:AMAG) opened at 34.15 on Wednesday. AMAG Pharmaceuticals has a 12-month low of $17.92 and a 12-month high of $34.42. The firm’s 50-day moving average price is $27.36 and its 200-day moving average price is $24.63. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of 78.51 and a beta of 0.83.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its earnings results on Thursday, November 3rd. The specialty pharmaceutical company reported $1.78 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.50 by $0.28. AMAG Pharmaceuticals had a return on equity of 11.10% and a net margin of 3.12%. The business had revenue of $143.80 million for the quarter, compared to the consensus estimate of $141.65 million. During the same period in the previous year, the company posted $1.02 earnings per share. The company’s revenue for the quarter was up 49.5% compared to the same quarter last year. On average, equities analysts predict that AMAG Pharmaceuticals will post $6.04 EPS for the current fiscal year.

In other AMAG Pharmaceuticals news, SVP Julie Krop sold 4,938 shares of the stock in a transaction dated Thursday, October 20th. The stock was sold at an average price of $24.80, for a total value of $122,462.40. Following the transaction, the senior vice president now owns 23,668 shares of the company’s stock, valued at $586,966.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 2.30% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Falcon Point Capital LLC increased its position in AMAG Pharmaceuticals by 86.8% in the second quarter. Falcon Point Capital LLC now owns 711,772 shares of the specialty pharmaceutical company’s stock worth $17,026,000 after buying an additional 330,691 shares in the last quarter. BlackRock Inc. increased its position in AMAG Pharmaceuticals by 528.5% in the first quarter. BlackRock Inc. now owns 4,299 shares of the specialty pharmaceutical company’s stock worth $101,000 after buying an additional 3,615 shares in the last quarter. DekaBank Deutsche Girozentrale increased its position in AMAG Pharmaceuticals by 24.7% in the second quarter. DekaBank Deutsche Girozentrale now owns 18,650 shares of the specialty pharmaceutical company’s stock worth $445,000 after buying an additional 3,700 shares in the last quarter. Systematic Financial Management LP increased its position in AMAG Pharmaceuticals by 19.2% in the second quarter. Systematic Financial Management LP now owns 73,985 shares of the specialty pharmaceutical company’s stock worth $1,769,000 after buying an additional 11,895 shares in the last quarter. Finally, SignalPoint Asset Management LLC increased its position in AMAG Pharmaceuticals by 6.9% in the second quarter. SignalPoint Asset Management LLC now owns 20,055 shares of the specialty pharmaceutical company’s stock worth $480,000 after buying an additional 1,288 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The legal version of this piece can be read at https://www.thecerbatgem.com/2016/11/26/amag-pharmaceuticals-inc-amag-receives-35-40-consensus-pt-from-brokerages.html.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

5 Day Chart for NASDAQ:AMAG

Receive News & Stock Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.